1 Min Read
Jan 25 (Reuters) - Novan Inc:
* NOVAN ANNOUNCES FIRST PATIENT DOSED IN PHASE 2 MOLLUSCUM CONTAGIOSUM TRIAL WITH SB206
* NOVAN INC - TOP LINE RESULTS ARE TARGETED FOR Q4 OF 2018 Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2018 Reuters. All Rights Reserved.